When did RECURSION PHARMACEUTICALS-A (RXRX) report earnings last quarter?
RECURSION PHARMACEUTICALS-A (RXRX) last reported earnings on 2/25/2026.
RECURSION PHARMACEUTICALS-A (RXRX) Earnings History & Surprises
NASDAQ:RXRX • US75629V1044
Current stock price
3.17 USD
0 (0%)
At close:
3.11 USD
-0.06 (-1.89%)
Pre-Market:
RXRX Earnings overview
Past quarterly earnings results for RECURSION PHARMACEUTICALS-A (RXRX), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Upcoming- Release Date
- May 4, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.28
- Revenue Estimate
- 17.809M
Last Reported
Most Recent- Release Date
- Feb 25, 2026
- Period
- Q4 / 2025
- EPS Reported
- -$0.21
- EPS Surprise
- 34.79%
- Revenue Surprise
- 41.71%
Beat Rate
Last 8 Quarters 63%
EPS and Revenue beats vs estimates
Quarterly Earnings Historical Results
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | -0.21 | -0.32 | 34.79% | 60.38% | 35.537M | 25.077M | 41.71% | 687.79% |
| Q3 2025 | -0.36 | -0.38 | 4.61% | -5.88% | 5.175M | 17.323M | -70.13% | -80.16% |
| Q2 2025 | -0.41 | -0.36 | -14.85% | -2.50% | 19.223M | 15.742M | 22.11% | 33.34% |
| Q1 2025 | -0.50 | -0.54 | 6.63% | -28.21% | 14.745M | 18.479M | -20.21% | 6.89% |
| Q4 2024 | -0.53 | -0.44 | -20.37% | -26.19% | 4.511M | 19.424M | -76.78% | -58.58% |
| Q3 2024 | -0.34 | -0.36 | 4.76% | 20.93% | 26.082M | 30.44M | -14.32% | 147.62% |
| Q2 2024 | -0.40 | -0.41 | 1.55% | -5.26% | 14.417M | 13.522M | 6.62% | 30.86% |
| Q1 2024 | -0.39 | -0.43 | 9.68% | -14.71% | 13.794M | 12.903M | 6.91% | 13.68% |
| Q4 2023 | -0.42 | -0.46 | 8.24% | -35.48% | 10.891M | 20.76M | -47.54% | -20.39% |
| Q3 2023 | -0.43 | -0.39 | -9.50% | -22.86% | 10.533M | 13.127M | -19.76% | -19.96% |
| Q2 2023 | -0.38 | -0.38 | 0.47% | - | 11.017M | 12.153M | -9.35% | 43.64% |
| Q1 2023 | -0.34 | -0.35 | 4.21% | -3.03% | 12.134M | 14.734M | -17.65% | 127.65% |
| Q4 2022 | -0.31 | -0.30 | -4.80% | 18.42% | 13.68M | 24.48M | -44.12% | 440.71% |
| Q3 2022 | -0.35 | -0.39 | 9.10% | -25.00% | 13.16M | 7.115M | 84.96% | 420.16% |
| Q2 2022 | -0.38 | -0.38 | 0.21% | -22.58% | 7.67M | 5.508M | 39.25% | 200.78% |
| Q1 2022 | -0.33 | 0.10 | -423.53% | 75.19% | 5.33M | 85.629M | -93.78% | 108.20% |
| Q4 2021 | -0.38 | -0.31 | -21.48% | - | 2.53M | 6.188M | -59.11% | - |
| Q3 2021 | -0.28 | -0.29 | 1.96% | - | 2.53M | 2.754M | -8.13% | - |
| Q2 2021 | -0.31 | -0.24 | -30.25% | - | 2.55M | 2.78M | -8.27% | 1,242.11% |
| Q1 2021 | -1.33 | - | - | 2.56M | - | - | ||
| Q2 2020 | - | - | 190K | - | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
3
Average EPS beat (4)
7.80%
Max EPS beat (4)
34.79%
Min EPS beat (4)
-14.85%
Revenue beat statistics
Revenue beat (4)
2
Average Revenue beat (4)
-6.63%
Max Revenue beat (4)
41.71%
Min Revenue beat (4)
-70.13%
Analysis
In the last 4 quarters, RXRX has beaten EPS estimates in 3 out of 4 releases
RXRX has beaten revenue estimates in 2 out of the last 4 releases
In the last 4 quarters, RXRX has beaten the EPS estimates by 7.8% on average.
In the last 4 quarters, RXRX reported -6.6% below the revenue estimates on average.
Related analysis
RECURSION PHARMACEUTICALS-A / RXRX Earnings FAQ
Did RXRX stock beat earnings estimates in the most recent quarter?
RECURSION PHARMACEUTICALS-A (RXRX) beat EPS estimates and beat revenue estimates in the most recent quarter.
Can you provide information on how often RECURSION PHARMACEUTICALS-A beats earnings estimates?
In the last 4 quarters, RECURSION PHARMACEUTICALS-A (RXRX) has beaten EPS estimates in 3 out of 4 releases.